Future Directions for Hypothermia following Severe Traumatic Brain Injury

Annie W. Chiu, MS, MPH, MD1 Holly E. Hinson, MD, MCR1

1 Department of Neurocritical Care, Neurology, and Emergency Medicine, Oregon Health & Science University, Portland, Oregon

Abstract

Traumatic brain injury (TBI) is a serious health care problem on both individual and public health levels. As a major cause of death and disability in the United States, it is associated with a significant economic and public health burden. Although the evidence to support the use of induced hypothermia on neurologic outcome after cardiac arrest is well established, its use in treating TBI remains controversial. Hypothermia has the potential to mitigate some of the destructive processes that occur as part of secondary brain injury after TBI. Hypothermia can be helpful in lowering intracranial pressure, for example, but its influence on functional outcome is unclear. There is insufficient evidence to support the broad use of prophylactic hypothermia for neuroprotection after TBI. Investigators are beginning to more carefully select patients for temperature modulating therapies, in a more personalized approach. Examples include targeting immunomodulation and scaling hypothermia to achieve metabolic targets. This review will summarize the clinical evidence for the use of hypothermia to limit secondary brain injury following acute TBI.

Keywords
► hypothermia
► cooling
► fever
► traumatic brain injury
► intracranial pressure

Rational for Hypothermia: The Biochemical Cascade

The damage incurred after TBI may be divided into two phases: primary and secondary injuries. The former occurs at the moment of impact, and the latter describes the cascade of damage that ensues after the primary insult. Secondary injury often includes cerebral edema, which may cause increased intracranial pressure (ICP) and decreased cerebral perfusion pressure, leading to ischemia. The cellular cascade of reactions starts within minutes to hours after injury, and can last days to weeks. Animal studies have shown that
sustained neuronal hyperexcitability—which is caused by an accumulation of excitatory neurotransmitters, excessive calcium influx into cells, and activation of kinase cascades—can occur within minutes (and last up to days) following injury. Different areas of the brain are physiologically maintained at slightly different temperatures, and such thermodynamic discrepancies may be exacerbated during injury. Longer acting processes responsible for ongoing secondary brain injury include mitochondrial dysfunction, production of free radicals, blood–brain barrier disruptions, diffusion restriction of cellular membranes, and release of proinflammatory cytokines. Theoretically, the processes producing secondary injury can be modified or even prevented.

In general, hypothermia is thought to be protective against several different aspects of secondary brain injury: reducing hyperexcitability and minimizing thermodynamic disparities, as well as altering the inflammatory response. Investigators have examined not only the role of hypothermia in interrupting secondary brain injury but also the timing of application of therapeutic hypothermia; both aspects are active areas of investigation.

**Hypothermia for Neuroprotection**

The existing literature evaluating prophylactic hypothermia can be generally divided into three categories: (1) hypothermia versus standard of care, (2) timing of hypothermia, and (3) localized versus systemic hypothermia. As body heat is lost to the environment through four basic mechanisms—radiation, convection, evaporation, and conduction—these mechanisms are commonly exploited to achieve systemic hypothermia. These techniques include exposure of skin (radiation), water sprays (evaporation), and fans (convection). Techniques utilizing mechanisms of conduction include water-circulating blankets, ice packs, intravascular catheters, and noninvasive surface cooling devices with conductive gel pads.

**Hypothermia versus Standard of Care**

Inspired by two randomized controlled trials (RCTs) that showed a 15\(^{10}\) and 18\(^{11}\) increase in favorable outcome in patients treated with hypothermia (compared with standard management) after severe head injury, a prospective, randomized trial of hypothermia for neuroprotection was conducted.\(^{12}\) In this robust multicenter controlled trial (National Acute Brain Injury Study using Hypothermia [NABISH-I]), patients with acute brain injury were randomized to standard care or surface-induced hypothermia (target temperature of 33°C, maintained for 47 ± 3 hours). In the hypothermia group, the target temperature was achieved more than 8 hours after primary injury.

The authors found that hypothermia did not improve the primary outcome measure, the Glasgow’s outcome scale (GOS) at 6 months after injury. In fact, the hypothermia group had a higher rate of hypertension and higher percentage of days with complications. Two unexpected benefits of hypothermia were also found: (1) fewer patients in the hypothermia group had elevated ICP and (2) of patients assigned to the hypothermia group, those who were hypothermic on admission had evidence of improved outcomes relative to the group who received standard care. However, this difference was not statistically significant (\(p = 0.09\)). Within this hypothermic-on-admission patient subgroup, those who were < 45 years of age showed a significant benefit compared with the standard care group in the same age range (\(p = 0.02\)).\(^{12,13}\)

Further complicating interpretation of these results, it is known that the induction of hypothermia can lead to episodes of hypovolemia and hypotension\(^{14}\)—even a single episode of hypotension can significantly worsen clinical outcome in TBI patients, increasing morbidity and possibly doubling mortality.\(^{6,14}\)

Though the NABISH-I trial was well designed, a common criticism was that the time to target temperature was slow, likely lagging behind the physiologic cascades that were already taking place after initial injury. In addition, the authors later commented that significant intercenter differences in outcomes were present, with more favorable outcomes achieved in larger centers. This was likely due to differences in treatment protocols in the management of hypotension and experience in the use of therapeutic hypothermia.\(^{14,15}\)

Although many other studies were conducted to evaluate therapeutic hypothermia in TBI,\(^{10,11,16–18}\) at that time, the NABISH-I trial was by far the largest (outcome data were obtained for 368 patients) and robustly designed. It heavily influenced the meta-analyses that followed.\(^{19,20}\)

Despite this high-quality evidence, the role of therapeutic hypothermia in TBI remained controversial. A salient example of this was in 2003 when two meta-analyses published within months of each other, using roughly the same studies, came to divergent conclusions.\(^{14,19,20}\)

In the Henderson et al meta-analysis, they concluded that there was no clear benefit of induced hypothermia on mortality. However, they found that hypothermia may result in a marginal benefit on neurologic outcome as measured by the GOS.\(^{19}\) In this meta-analysis, eight studies were included, resulting in a total of 748 patients.\(^{19}\) Given the large number of patients in the NABISH-I trial, it accounted for nearly half of the patients included in the meta-analysis.\(^{14}\) In contrast, the McIntyre et al meta-analysis concluded that therapeutic hypothermia may confer a benefit in mortality and neurologic outcomes. In this meta-analysis, 12 studies were included, totaling 1,069 patients.\(^{20}\) The NABISH-I patients accounted for approximately 34% of all patients.\(^{14}\)

Some authors believe that the Henderson et al analysis included studies with a small number of patients, disparate inclusion criteria, and different treatment protocols. Particularly, problematic was that studies with patients with normal ICPs were combined with studies that required elevated ICP as an inclusion criterion. As variations in ICP may reflect the severity of pathologic progresses that take place after TBI, patients with normal ICP post-TBI may be a distinct category of patients, separate from those with elevated ICP.\(^{14}\) Therefore, combining patients with high ICP with the normal ICP group may increase the heterogeneity of
the subject pool. In addition to the heterogeneous inclusion criteria, differing treatment protocols, and varied sample size between studies,14 the time to target temperature was felt to be a likely, if not the essential, factor influencing neurologic outcomes.13–15,21

Timing of Hypothermia

To address the lengthy time to target temperature in their 2001 study, Clifton et al designed the National Acute Brain Injury Study: Hypothermia II (NABIS: H II), a randomized, multicenter clinical trial where the target temperature (33°C) was achieved in approximately 4.5 hours, cutting the time to target temperature almost in half from the NABISH-I trial. In reducing the time to target temperature, the authors hoped that arresting secondary injury early might improve outcomes. Unfortunately, NABIS: H II was terminated early due to concern about the study’s slow recruitment and the feasibility of extending funding without an interim analysis. The study was terminated for futility after an interim analysis that included only 97 patients, despite a planned sample size of 240 patients.

In NABIS: H II, Clifton et al found no significant difference in poor outcomes between subjects in the hypothermia group compared with the normothermia group; similarly, mortality between the two groups was not significantly different. However, their data suggest that hypothermia may lead to a more complex hospital course: subjects who underwent prophylactic hypothermia had significantly increased rates of raised ICP, received more interventions for raised ICP, and an increase in total rate of complications.22 In some aspects, these results were opposite from their 2001 study, in which the hypothermia group had fewer incidents of elevated ICP.12 Given the hypothermia-induced hypotension observed in their earlier study,12 the authors felt that the most likely explanation for the increased ICP observed in their 2011 study was the aggressive measures taken to reduce such hypotension.22

Further, patients with diffuse brain injury who were randomized to the hypothermia group had a greater number of poor outcomes (as defined by GOS scores) and increased mortality compared with their normothermic counterparts (p = 0.09 and p = 0.08, respectively). A possible explanation for these differing outcomes may be that many patients who undergo surgical evacuation may also have bone flaps that were left out, thereby allowing more room for the brain to swell and avoiding increased ICP. Notably, in the surgical intervention group, bone flaps were left out in one-third of the hypothermia patients and nearly half of the normothermia patients.22

In both NABISH-I and NABIS: H II, the target temperature was maintained for only 48 hours, a duration that may be too short to positively affect their primary outcome (the five-category GOS score at 6 months).23 A Chinese study comparing short-term (~2 days) versus long-term (~5 days) hypothermia found that long-term therapy significantly improved outcome, as measured by the GOS.24 They also found that ICP significantly increased in the short-term hypothermia group during rewarming, a change that was unique to the short-term group and not found in the long-term group.24 This finding is similar to the increased ICP found in NABIS: H II’s hypothermia patients.

In animal models, ischemia has been found to occur in the context of hematoma expansion, its removal, and subsequent reperfusion.25 As intraischemic hypothermia has been shown to improve secondary injury in animal models,26 it is possible that a similar effect was seen in vivo in this study. Given that diffuse brain injury is not associated with ischemia, the authors felt that this was a possible explanation for the discrepant outcomes in the subgroup analysis.22

Selective Brain Cooling versus Systemic Hypothermia

To mitigate the risk associated with systemic hypothermia (e.g., shock, infection, coagulopathy), subsequent rewarming (e.g., infection, shock), and to achieve a faster target temperature, some groups have investigated selective brain cooling as an alternate means of achieving the goals of hypothermia. Multiple methods for selective cerebral hypothermia have been proposed, including surface cooling, intranasal cooling, transvenous endovascular cooling,28 and brain surface irrigation.29

Although several studies have examined selective cooling,29,30 the highest quality data to date comes from a 2006 investigation in China. Researchers conducted a randomized, controlled, double-blinded study comparing selective brain cooling against systemic cooling and normothermia (control, 37°C) in patients with severe TBI (history of TBI, GCS ≤ 8 on admission, and brain injury evident on CT scan within 24 hours of admission). To selectively cool the brain to 33 to 35°C, patients wore a cooling cap with circulating 4°C circulating water and a neckband with ice strips. Target temperature in systemic hypothermia (33–35°C) group was achieved through use of a cooling blanket and ice bags.31

Researchers found that GOS were highest (GOS score of 4 or 5) in the selective brain cooling group 2 years after injury compared with systemic hypothermia and the control groups (72.7% in selective brain cooling group, 57.1% in systemic hypothermia group, and 34.8% in control group). In addition, the frequency of good neurologic outcome (defined as GOS score of 4 or 5) was significantly higher in the hypothermia groups compared with the normothermia group. The selective brain cooling group also had significantly lower ICPs relative to the control group. This result should be interpreted with caution, however, as the average ICP value in all groups, at all time points, was above 20 mm Hg.31
Systemic complications appeared to be mitigated with focal cooling—the group found that rates of pneumonia were lowest in the selective brain cooling group. Though both hypothermia groups had evidence of thrombocytopenia, platelet counts returned to normal within 3 days of re-warming. Finally, the authors observed that superoxide dismutase levels were significantly higher on days 3 and 7 postinjury in the hypothermia groups compared with the normothermia groups, which might reflect hypothermia’s ability to reduce free radical generation and lipid peroxidation. Though promising, the evidence at present is insufficient to formulate guidelines regarding selective versus systemic hypothermia in TBI.

**Hypothermia for Rescue Therapy**

**Elevated Intracranial Pressure**

ICP measurements exceeding 20 mm Hg are regarded as intracranial hypertension, though emerging evidence suggests this threshold might not apply to all patients. After TBI, ICP can rise due to hematoma expansion, cerebral edema, or impaired autoregulation. Retrospective studies from large databanks have shown an association between elevated ICP (>20 mm Hg) initially or during clinical deterioration and both neurologic worsening and poor outcome. Though elevated ICP is associated with worse outcome, it remains unclear whether increased ICP is reflective of ongoing pathological processes after TBI, an independent factor complicating a patient’s clinical course, or both. In the most recent iteration of the BTF guidelines, treatment of ICP >22 mm Hg is recommended as level II B recommendation. Values exceeding 22 mm Hg are associated with increased mortality. Historically, high ICP has been treated with a tiered approach, moving from less invasive to more invasive measures (e.g., head elevation, osmotic therapy, and surgical intervention).

Hypothermia is a tool in the armamentarium for both cerebral edema and elevated ICP. Numerous studies have demonstrated hypothermia to be effective in controlling elevated ICP, and can be used to control intracranial hypertension even in the later stages after initial injury. A meta-analysis of eight RCTs examining therapeutic hypothermia for severe TBI found that hypothermia can lower ICP even in patients refractory to first-line therapies. However, it remained unclear whether functional outcome is improved by use of hypothermia in this context.

To address the question of functional outcome, European investigators conducted the Eurotherm3235 trial, a large, multicenter RCT where patients with severe TBI and refractory raised ICP (>20 mm Hg for >5 minutes) were randomized to receive second-tier interventions or second-tier interventions with therapeutic hypothermia (32–35°C). In contrast to common practice in the United States, second-tier interventions included osmotherapy and inotropes. In the hypothermia group, the core temperature was reduced to the highest temperature necessary to maintain an ICP of ≤20 mm Hg. Hypothermia was maintained for at least 48 hours and continued for as long as necessary to keep ICP within goal. For patients in both groups who could not achieve ICP ≤20 mm Hg, stage 3 interventions were pursued. Stage 3 interventions included barbiturate therapy and decompressive craniectomy. The primary outcome was the GOS-extended score at 6 months.

Compared with controls, fewer hypothermia patients required escalation of care to control ICP. However, the trial was terminated early due to safety concerns: the distribution of GOS-extended scores and number of adverse events reflected a worse outcome in the hypothermia group. Although the Eurotherm3235 data support hypothermia’s role in effectively controlling ICP, it further fuels the debate as to whether reducing ICP translates into improved neurologic outcomes.

**Immunomodulation: Hypothermia’s Effect on Cytokines or Inflammatory Markers**

As a result of the initial injury, a robust inflammatory cascade occurs both centrally and peripherally. This cascade is characterized by a spectrum of increased cytokine production, as demonstrated in both animal models and clinical studies. Analysis of post-TBI brain tissue in animal models reveals robust local inflammation about the area of injury. In humans, elevated levels of proinflammatory cytokines such as interleukin (IL)-1, IL-6, tumor necrosis factor-α, and IL-10 (compensatory anti-inflammatory response) that may be associated with immunosuppression. Experimentally, hypothermia after moderate TBI (using a fluid percussion injury model) was associated with significantly higher levels of growth-associated protein (GAP-43) in brain parenchyma. GAP-43 is thought to be a marker of neuronal sprouting, leading the authors to conclude that hypothermia may encourage neuronal sprouting post-TBI. The examiners also found lower levels of IL-6 and cytokine signaling 3 (SOCS3) in the hypothermia group. Suppressor of SOCS3 is believed to be a key negative regulator, and its expression is believed to inhibit cell survival and outgrowth after injury. This is in accordance with previous data which showed that post-TBI hypothermia can attenuate plasma IL-6 levels in humans. Given the complexity of the cellular cascades, further investigation is needed to clarify hypothermia’s role post-TBI.

**Metabolic-Targeted Hypothermia**

In contrast to targeting a specific temperature for all patients, Feng et al offered a more personalized approach to therapeutic hypothermia in a pilot RCT. As hypothermia is thought to reduce the metabolic rate, the investigators tailored the cooling to achieve a target metabolic rate rather than a strict temperature goal.
In this single-blind RCT, severe TBI patients (defined as GCS 3–8) were assigned to either the metabolic-targeted hypothermia treatment (MTHT) group or the body temperature-targeted hypothermia treatment (BTHT) control group. In the MTHT group, hypothermia was employed to achieve 50 to 60% of a patient’s rest metabolic rate for 5 days. (Each patient’s resting metabolic rate was measured by an indirect calorimetry management system.) In the set temperature group, 32 to 35°C was set as the target temperature and maintained for 5 days. The primary outcome of the study was mortality. Nested within this study was a metabolomics analysis where blood samples were analyzed through use of a proton nuclear magnetic resonance. This was done to explore changes in metabolic patterns in both the hypothermia and control groups.

In the pilot phase, the investigators found that the mortality rate was lower in the MTHT group compared with the temperature-targeted hypothermia treatment group \(p = 0.049\). Though the sample size was relatively small (88 patients), the results are encouraging. Of note, of the 42 MTHT cases who completed therapy, 4 cases withdrew, 2 cases abandoned treatment, and 2 cases died. The investigators are actively recruiting patients for a more definitive study.\(^6\)

**Fever/Targeted Temperature Management**

Some investigators have posited that the benefits of hypothermia are related to strict fever avoidance. Fever is common in severe TBI and may contribute to secondary brain injury.\(^6\) Even small fluctuations in systemic and local (brain) temperature can affect neuronal vulnerability after injury.\(^6\) To assess the effect of fever on patient outcome and mortality, Li and Jiang (2012) conducted a retrospective analysis of data from the Chinese Head Trauma Data Bank. Patients were divided into three groups: normothermia (36.3–37.2°C) and mild fever (37.3–38.0°C), moderate fever (38.1–39.0°C), and high fever (>39.0°C). Statistically significant differences in the mortality rate and unfavorable outcomes (defined as severe disability, vegetative state, and death as measured on the GOS [1–3]) were found between the groups: Both mortality rates and unfavorable outcomes increased with the degree of pyrexia.\(^6\) Their results suggest that posttraumatic hyperthermia exerts a deleterious effect that is proportional to both its degree and duration. The mechanism of its effect likely involves the many and complex processes involved in secondary injury.

Strict fever avoidance contrasts to standard management in that standard care only addresses elevated temperatures after they occur, usually with antipyretic medication. In contrast, targeted temperature management (TTM) is a process that achieves a specific temperature, often with the intent to tightly control temperature to mitigate potentially harmful processes that occur during secondary injury.

In 2016, Miyata et al compared the effect of therapeutic hypothermia (32–34°C) and TTM (35.5–37°C) on GOS scores at 6 months in patients with severe TBI. They found no significant difference in the likelihood of poor neurologic outcome and mortality between patients treated with hypothermia and those treated with fever control. In addition, they found that the rate of complications (secondary outcome) was significantly higher in the hypothermia group compared with the fever control group, suggesting that hypothermia is not only noninferior to fever control but that hypothermia may cause harm. Although the results of this study are compelling, its conclusions must be interpreted with caution: though the goal was to achieve target temperature within 6 hours of injury, over half (65%) of the patients in the hypothermia group took over 6 hours to reach their target temperature.

A recent cohort observational study from the Nationwide Japan Neurotrauma Data Bank offers further insight. In this observational study, investigators divided TBI patients into two groups: those who underwent therapeutic temperature management of any kind versus conventional management. The former group included both therapeutic normothermia (<37°C) and therapeutic hypothermia (<35°C) patients. The control group was not exposed to mechanical cooling devices but did receive medical antipyretic drugs if medically necessary. No significant difference in GOS was found between the two groups at discharge.\(^6\)

**Conclusion**

Though there is compelling rationale that hypothermia has the potential to mitigate the destructive metabolic processes that occur during secondary injury, there has yet to be strong and clear evidence to support its broad use in severe TBI to modify long-term outcomes. Hypothermia does seem to be a reasonable option to control elevated ICP in select patients. The future of hypothermia and TTM likely lay in careful patient selection and customization to achieve specific clinical targets. This approach may take the form of exploring hypothermia’s role in post-TBI immunomodulation and achieving metabolic targets, in a more personalized approach to therapy.

**References**

36 Lazaridis C, Robertson CS. Hypothermia for increased intracranial pressure: is it dead? Curr Neurol Neurosci Rep 2016;16(09):78
40 Taupin P, Toumound S, Serrano A, Benavides J, Zavala F. Increase in IL-6, IL-1 and TNF levels in rat brain following traumatic lesion. Influence of pre- and post-traumatic treatment with Ros 4864, a peripheral-type (p site) benzodiazepine ligand. J Neuroimmunol 1999;42(02):177–185
63 Li J, Jiang JY. Chinese Head Trauma Data Bank: effect of hyperthermia on the outcome of acute head trauma patients. J Neurotrauma 2012;29(01):96–100